Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,483.28 65.75 0.46%
TOPIX 1,169.56 2.97 0.25%
HANG SENG 22,760.24 64.23 0.28%

CytoSorbents to Host Shareholder Update Conference on Wednesday, August 21st at 4:15 p.m. Eastern


CytoSorbents to Host Shareholder Update Conference on Wednesday, August 21st at 4:15 p.m. Eastern

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 08/14/13 -- CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company working to save lives through blood purification, today announced that management will host a shareholder update conference call on Wednesday, August 21st at 4:15 p.m. Eastern. Management kindly asks all interested participants to submit their questions to Alliance Advisors at valter@allianceadvisors.net.

Conference Call Details: Date: Wednesday, August 21, 2013 Time: 4:15 p.m. Eastern Participant Dial-In: (480) 629-9712 Live Webcast: http://public.viavid.com/index.php?id=105816 Submit Questions to: valter@allianceadvisors.net

It is recommended that participants dial in approximately 10 minutes prior to the start of the 4:15 p.m. Eastern call. There will also be a simultaneous live webcast of the conference call which can be accessed through the following audio feed link and archived recording of the conference call available under the Investor Relations section of the company website at http://public.viavid.com/index.php?id=105816.

About CytoSorbents Corporation CytoSorbents is a critical care focused therapeutic device company specializing in blood purification. CytoSorb(R), the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine filter, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the mortality is extremely high, yet no effective treatments exist. The goal of CytoSorb(R) is to prevent or treat multiple organ failure, the cause of nearly half of all deaths in the intensive care unit, with little available to improve clinical outcome. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend(TM), ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: www.cytosorbents.com

Company Contact: CytoSorbents Corporation Dr. Phillip Chan Chief Executive Officer (732) 329-8885 ext. *823 pchan@cytosorbents.com

Investor Contact: Alliance Advisors, LLC Alan Sheinwald (914) 669-0222 asheinwald@allianceadvisors.net

Valter Pinto (914) 669-0222 x201 valter@allianceadvisors.net

Media Contact: JQA Partners Jules Abraham (917) 885-7378 jabraham@jqapartners.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement